KRAS and neoplasm: Importantly, RT11-i markedly inhibited the growth of the three oncogenic KRas mutant tumour xenografts, showing ∼46–70% more tumour-growth inhibition (TGI) (Fig. 6a) and ∼42–63% greater reduction in tumour weight, compared to those after treatment with TMab4-i (Supplementary Fig. 10b).